Physician profile

Sumeet Kaur

Dentist · Rocklin, CA

NPI 1003104399

$356.62

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$171.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Straumann USA LLC $97.42 2022
Align Technology, INC. $84.04 2019-2023 Itero Element 5d Plus
3m Company $77.10 2019-2023 Scotchbond Universal Plus, 3m Filtek, Filtek
Solventum Corporation $43.94 2024 Filtek, 3m Scotchbond, 3m Espe Filtek Supreme Ultra Universal Restorative
Biotissue Holdings INC. $24.92 2023
Implant Direct Sybron International LLC $14.69 2020
Ultradent Products INC $14.51 2023 Opalescence

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sumeet Kaur

$356.62

in general payments reported 2019-2025

Years
2019-2024
Top company
Straumann USA LLC

https://glasscript.com/doctor/505689/sumeet-kaur

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.